December 1, 2014

homepage

February 6, 2020

ALK-Abelló and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – February 5, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment […]

Continue Reading
January 13, 2020

ZebiAI Therapeutics, Inc. and X-Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery

New venture capital-backed artificial intelligence company to utilize X-Chem’s leading DNA encoded library screening service WALTHAM, Mass. – ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately held companies, today announced a multiyear service and license agreement. The agreement provides ZebiAI access to X-Chem’s proprietary DNA Encoded Library technology (DEX™) for the […]

Continue Reading
September 4, 2019

Maruho and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – September 4, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Maruho Co., Ltd. (Maruho) to discover lead compounds for novel and challenging targets […]

Continue Reading